REPLIGEN CORP
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $738.3 | $634.4 | $632.4 | $801.5 | $670.5 |
| Operating income | $55.2 | -$35.1 | $47.7 | $224.7 | $167.2 |
| Net income | $48.9 | -$25.5 | $35.6 | $186.0 | $128.3 |
| Cash Flow Statement | |||||
| Free cash flow | $93.9 | $149.7 | $77.7 | $87.2 | $51.9 |
| Share repurchases | $0.0 | $0.0 | $14.4 | $0.0 | $0.0 |
Shares outstanding 56.4M · Free float 86.1%
Annual filing data through FY ended December 31, 2025; float as of September 20, 2026.
Coverage
October 6, 2026
Deals
Repligen Completes $1.5 Billion BioLife Solutions Acquisition
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
July 22, 2026
Deals
Repligen to Buy BioLife Solutions in $1.5 Billion Mixed Deal